Tenderwize
Retour à la recherche

Open house drug discount agreements Formoterol and Fluticason, ATC R03AK11

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 05, 2027 · 188 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol und Fluticason, ATC R03AK11

60/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

No indication of expected volume or historical spend; revenue may be low or zero.

Open-house agreements automatically terminate if a competitive discount contract (nationwide or regional) for the same...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive discount agreements for pharmaceutical products containing Formoterol and Fluticason (ATC R03AK11)
  • Contracting with all eligible pharmaceutical companies on identical terms
Afficher le résumé complet

This is an open-house model (not a public procurement procedure) by AOK Bayern for non-exclusive drug discount agreements on Formoterol and Fluticason (ATC R03AK11). All eligible pharmaceutical companies can join by submitting a signed contract, annex, and declaration of reliability. Contracts run from May 2025 to April 2027, with enrollment possible until March 5, 2027. No estimated value, award criteria, or competitive selection is involved.

Risques

No indication of expected volume or historical spend; revenue may be low or zero.

Open-house agreements automatically terminate if a competitive discount contract (nationwide or regional) for the same...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company

Certifications

  • Documents in German or with certified translation

Administrative

  • Submit signed contract, annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria (open-house model)

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house drug discount agreements Formoterol and Fluticason, ATC R03AK11

Non-exclusive discount agreements for pharmaceutical products containing Formoterol and Fluticason. All eligible pharma companies can join. Contract period: 2025-05-01 to 2027-04-30. Latest enrolment: 2027-03-05.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Apr 2025 - Apr 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria (open-house model)

Date limite

Deadline Mar 05, 2027

Détails de la procédure

Date de publication
18 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
176919-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30